The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats

Eric G. Mohler, Phillip M. Baker, Kimberly S. Gannon, Simon S. Jones, Sharon Shacham, John A. Sweeney, Michael E. Ragozzino

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Rationale Accumulating evidence indicates that schizophrenia and autism spectrum disorder patients are marked by cognitive deficits in working memory and strategy switching. There is accumulating evidence that 5-hydroxytryptamine (5-HT)6 receptors may serve as a useful target to improve cognitive functioning. Objectives In the present experiments, the novel 5-HT6 antagonist, PRX-07034, was examined for its selectivity of the 5-HT6 receptor, as well as its effect on delayed spontaneous alternation and strategy switching. Methods The binding affinity of PRX-07034 to the 5-HT6 receptor, other 5-HT receptors, as well as other G-protein coupled receptors, ion channels, and transporters was transfected HEK-293 cells. In separate behavioral experiments, rats received different doses of PRX-07034 (0.1, 1, or 3 mg/kg, i.p.) 30 min prior to delayed spontaneous alternation testing or prior to the acquisition and switch phases in a place-response switch test. Results The results indicated that PRX-07034 is both a potent (Ki=4-8 nM) and highly selective 5-HT6 receptor antagonist (≥100-fold selectivity for the 5-HT6 receptor compared to 68 other GPCRs, ion channels, and transporters, except D3 (Ki=71 nM) and 5-HT1B (Ki=260 nM) receptors. For cyclic AMP quantification, PRX-07034 demonstrated antagonist activity (IC50=19 nM) without an effect on basal levels and did not show any agonist activity up to 10 μM. PRX-07034 at 1 and 3 mg/kg (but not 0.1 mg/kg) significantly enhanced delayed spontaneous alternation. The drug at 1 and 3 mg/kg also enhanced switching between a place and response strategy, but did not affect initial learning of either a place or response discrimination. Conclusions These findings demonstrate that PRX-07034 is a selective 5-HT 6 receptor antagonist that may represent a novel treatment for enhancing working memory and cognitive flexibility.

Original languageEnglish (US)
Pages (from-to)687-696
Number of pages10
JournalPsychopharmacology
Volume220
Issue number4
DOIs
StatePublished - 2012

Fingerprint

Short-Term Memory
Ion Channels
HEK293 Cells
Serotonin Receptors
G-Protein-Coupled Receptors
Cyclic AMP
Inhibitory Concentration 50
serotonin 6 receptor
Schizophrenia
Learning
Pharmaceutical Preparations

Keywords

  • Autism spectrum disorder
  • Learning
  • Memory
  • Schizophrenia
  • Serotonin
  • Set-shifting

ASJC Scopus subject areas

  • Pharmacology

Cite this

Mohler, E. G., Baker, P. M., Gannon, K. S., Jones, S. S., Shacham, S., Sweeney, J. A., & Ragozzino, M. E. (2012). The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats. Psychopharmacology, 220(4), 687-696. https://doi.org/10.1007/s00213-011-2518-7

The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats. / Mohler, Eric G.; Baker, Phillip M.; Gannon, Kimberly S.; Jones, Simon S.; Shacham, Sharon; Sweeney, John A.; Ragozzino, Michael E.

In: Psychopharmacology, Vol. 220, No. 4, 2012, p. 687-696.

Research output: Contribution to journalArticle

Mohler, EG, Baker, PM, Gannon, KS, Jones, SS, Shacham, S, Sweeney, JA & Ragozzino, ME 2012, 'The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats', Psychopharmacology, vol. 220, no. 4, pp. 687-696. https://doi.org/10.1007/s00213-011-2518-7
Mohler, Eric G. ; Baker, Phillip M. ; Gannon, Kimberly S. ; Jones, Simon S. ; Shacham, Sharon ; Sweeney, John A. ; Ragozzino, Michael E. / The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats. In: Psychopharmacology. 2012 ; Vol. 220, No. 4. pp. 687-696.
@article{10d9969f94774c01862660296399ca72,
title = "The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats",
abstract = "Rationale Accumulating evidence indicates that schizophrenia and autism spectrum disorder patients are marked by cognitive deficits in working memory and strategy switching. There is accumulating evidence that 5-hydroxytryptamine (5-HT)6 receptors may serve as a useful target to improve cognitive functioning. Objectives In the present experiments, the novel 5-HT6 antagonist, PRX-07034, was examined for its selectivity of the 5-HT6 receptor, as well as its effect on delayed spontaneous alternation and strategy switching. Methods The binding affinity of PRX-07034 to the 5-HT6 receptor, other 5-HT receptors, as well as other G-protein coupled receptors, ion channels, and transporters was transfected HEK-293 cells. In separate behavioral experiments, rats received different doses of PRX-07034 (0.1, 1, or 3 mg/kg, i.p.) 30 min prior to delayed spontaneous alternation testing or prior to the acquisition and switch phases in a place-response switch test. Results The results indicated that PRX-07034 is both a potent (Ki=4-8 nM) and highly selective 5-HT6 receptor antagonist (≥100-fold selectivity for the 5-HT6 receptor compared to 68 other GPCRs, ion channels, and transporters, except D3 (Ki=71 nM) and 5-HT1B (Ki=260 nM) receptors. For cyclic AMP quantification, PRX-07034 demonstrated antagonist activity (IC50=19 nM) without an effect on basal levels and did not show any agonist activity up to 10 μM. PRX-07034 at 1 and 3 mg/kg (but not 0.1 mg/kg) significantly enhanced delayed spontaneous alternation. The drug at 1 and 3 mg/kg also enhanced switching between a place and response strategy, but did not affect initial learning of either a place or response discrimination. Conclusions These findings demonstrate that PRX-07034 is a selective 5-HT 6 receptor antagonist that may represent a novel treatment for enhancing working memory and cognitive flexibility.",
keywords = "Autism spectrum disorder, Learning, Memory, Schizophrenia, Serotonin, Set-shifting",
author = "Mohler, {Eric G.} and Baker, {Phillip M.} and Gannon, {Kimberly S.} and Jones, {Simon S.} and Sharon Shacham and Sweeney, {John A.} and Ragozzino, {Michael E.}",
year = "2012",
doi = "10.1007/s00213-011-2518-7",
language = "English (US)",
volume = "220",
pages = "687--696",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats

AU - Mohler, Eric G.

AU - Baker, Phillip M.

AU - Gannon, Kimberly S.

AU - Jones, Simon S.

AU - Shacham, Sharon

AU - Sweeney, John A.

AU - Ragozzino, Michael E.

PY - 2012

Y1 - 2012

N2 - Rationale Accumulating evidence indicates that schizophrenia and autism spectrum disorder patients are marked by cognitive deficits in working memory and strategy switching. There is accumulating evidence that 5-hydroxytryptamine (5-HT)6 receptors may serve as a useful target to improve cognitive functioning. Objectives In the present experiments, the novel 5-HT6 antagonist, PRX-07034, was examined for its selectivity of the 5-HT6 receptor, as well as its effect on delayed spontaneous alternation and strategy switching. Methods The binding affinity of PRX-07034 to the 5-HT6 receptor, other 5-HT receptors, as well as other G-protein coupled receptors, ion channels, and transporters was transfected HEK-293 cells. In separate behavioral experiments, rats received different doses of PRX-07034 (0.1, 1, or 3 mg/kg, i.p.) 30 min prior to delayed spontaneous alternation testing or prior to the acquisition and switch phases in a place-response switch test. Results The results indicated that PRX-07034 is both a potent (Ki=4-8 nM) and highly selective 5-HT6 receptor antagonist (≥100-fold selectivity for the 5-HT6 receptor compared to 68 other GPCRs, ion channels, and transporters, except D3 (Ki=71 nM) and 5-HT1B (Ki=260 nM) receptors. For cyclic AMP quantification, PRX-07034 demonstrated antagonist activity (IC50=19 nM) without an effect on basal levels and did not show any agonist activity up to 10 μM. PRX-07034 at 1 and 3 mg/kg (but not 0.1 mg/kg) significantly enhanced delayed spontaneous alternation. The drug at 1 and 3 mg/kg also enhanced switching between a place and response strategy, but did not affect initial learning of either a place or response discrimination. Conclusions These findings demonstrate that PRX-07034 is a selective 5-HT 6 receptor antagonist that may represent a novel treatment for enhancing working memory and cognitive flexibility.

AB - Rationale Accumulating evidence indicates that schizophrenia and autism spectrum disorder patients are marked by cognitive deficits in working memory and strategy switching. There is accumulating evidence that 5-hydroxytryptamine (5-HT)6 receptors may serve as a useful target to improve cognitive functioning. Objectives In the present experiments, the novel 5-HT6 antagonist, PRX-07034, was examined for its selectivity of the 5-HT6 receptor, as well as its effect on delayed spontaneous alternation and strategy switching. Methods The binding affinity of PRX-07034 to the 5-HT6 receptor, other 5-HT receptors, as well as other G-protein coupled receptors, ion channels, and transporters was transfected HEK-293 cells. In separate behavioral experiments, rats received different doses of PRX-07034 (0.1, 1, or 3 mg/kg, i.p.) 30 min prior to delayed spontaneous alternation testing or prior to the acquisition and switch phases in a place-response switch test. Results The results indicated that PRX-07034 is both a potent (Ki=4-8 nM) and highly selective 5-HT6 receptor antagonist (≥100-fold selectivity for the 5-HT6 receptor compared to 68 other GPCRs, ion channels, and transporters, except D3 (Ki=71 nM) and 5-HT1B (Ki=260 nM) receptors. For cyclic AMP quantification, PRX-07034 demonstrated antagonist activity (IC50=19 nM) without an effect on basal levels and did not show any agonist activity up to 10 μM. PRX-07034 at 1 and 3 mg/kg (but not 0.1 mg/kg) significantly enhanced delayed spontaneous alternation. The drug at 1 and 3 mg/kg also enhanced switching between a place and response strategy, but did not affect initial learning of either a place or response discrimination. Conclusions These findings demonstrate that PRX-07034 is a selective 5-HT 6 receptor antagonist that may represent a novel treatment for enhancing working memory and cognitive flexibility.

KW - Autism spectrum disorder

KW - Learning

KW - Memory

KW - Schizophrenia

KW - Serotonin

KW - Set-shifting

UR - http://www.scopus.com/inward/record.url?scp=84871901603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871901603&partnerID=8YFLogxK

U2 - 10.1007/s00213-011-2518-7

DO - 10.1007/s00213-011-2518-7

M3 - Article

C2 - 21989804

AN - SCOPUS:84871901603

VL - 220

SP - 687

EP - 696

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -